Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?

Clara Gitahy Falcao Faria,Luisa Weiner,Julien Petrignet,Coraline Hingray,Ángel Ruiz De Pellon Santamaria,Bruno O Villoutreix,Philippe Beaune,Marion Leboyer,Hervé Javelot

doi:10.1016/j.mehy.2021.110508

Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?

Clara Gitahy Falcao Faria, Luisa Weiner + Show 7 more

Open Access

https://doi.org/10.1016/j.mehy.2021.110508

Copy DOI

Journal: Medical Hypotheses	Publication Date: Jan 24, 2021
Citations: 9	License type: cc-by-nc

Affiliation: Universidade Federal do Rio de Janeiro, Université de Tours, Centre Hospitalier Universitaire de Nancy, Hôpital Robert-Debré, Université Paris Cité, Inserm, Centre de Recherche des Cordeliers, Mondor Institute of Biomedical Research, Fondation FondaMental, Université Paris-Est Créteil, Assistance Publique – Hôpitaux de Paris, Observatoire Régional de la Santé d’Alsace, University of Strasbourg

#Cationic Amphiphilic Drugs #Cationic Drugs + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Several studies have reported that certain psychoactive drugs could have a protective effect against SARS-CoV-2. Herein, we propose that antihistamines (anti-H1) and cationic amphiphilic drugs (CAD), specifically, have the capacity to disrupt virus entry and replication. In addition, several of these molecules have limited side effects and as such could be promising prophylactic candidates against SARS-CoV-2 infection.

Full Text